[New chemotherapy approaches to psychoses]

Area of Science:

• Pharmacology
• Neuroscience
• Psychiatry

Context:

• Atypical antipsychotics represent a newer class of drugs for treating schizophrenia.
• These medications aim to improve upon the limitations of older antipsychotic agents, particularly regarding side effects and efficacy on negative symptoms.
• The concept of 'atypical' is debated, potentially referring to a unique dose-efficacy-side effect profile rather than a strict pharmacological category.

Purpose:

• To critically evaluate the concept and characteristics of atypical antipsychotics.
• To discuss the dopaminergic hypothesis of schizophrenia and the role of monoaminergic receptor interactions.
• To review the current evidence regarding the efficacy of atypical antipsychotics, especially on negative symptoms and optimal dosing.

Summary:

• Atypical antipsychotics exhibit unique properties including efficacy in refractory patients and on negative symptoms, with reduced extrapyramidal side effects and prolactin elevation.
• Their therapeutic effects are likely associated with combined antagonism of serotonin 5HT2 and dopamine D2 receptors.
• While efficacy on negative symptoms remains controversial and requires further investigation, some agents like risperidone demonstrate clear effectiveness within a specific dosage range (6 +/- 2 mg daily).

Impact:

• Atypical antipsychotics may offer a significant advancement in schizophrenia management, potentially simplifying treatment regimens.
• Improved patient adherence and reduced relapse rates are anticipated due to a better side effect profile and defined dosing.
• These agents hold the promise of reducing the need for additional therapies, leading to fewer hospitalizations and improved patient outcomes.